The liver is the body’s control tower for metabolism, powering vital functions like converting nutrients to glucose, storing fat and breaking down toxins. Over a third of the world, however, is thought to be affected by conditions including metabolic dysfunction-associated steatotic liver disease (MASLD), which jeopardize key liver functions as the condition progresses.

Hepatocyte organoids – the miniature, 3D models of the organ – hold immense promise for accelerating drug development and advancing regenerative therapies. In a study published in Nature, Keio University researchers unveiled a method to proliferate these hard-to-grow organoids by a million-fold in just 3-4 weeks while maintaining key liver functions. “These organoids are potentially the closest laboratory representations of the liver and its multifunctionality,” says senior author Professor Toshiro Sato of the Keio University School of Medicine.

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, will be exhibiting at the American Association for Cancer Research (AACR) Annual Meeting 2025 from April 25–30, 2025. The seasoned Insilico Business Development team led by Petrina Kamya, Ph.D, Global Head of AI Platforms & VP, Insilico Medicine Canada, and Michelle Chen, Ph.D, Chief Business Officer of Insilico Medicine, will be welcoming collaboration and industrial insight conversations at Booth #334, McCormick Place Convention Center, Chicago.